tirzepatide summit trial SURPASS to SURMOUNT: The Trials To Know AHA 24 Late-Breaking Discussion: SUMMIT:
Description
You can approximate this at home
The weight-loss effect of GLP-1RAs also benefits NASH improvement, by reducing appetite and increasing energy expenditure to promote weight loss, thereby indirectly ameliorating NASH
Eli Lilly and Company (2023) A phase 3, open-label study of once daily LY3502970 compared with insulin glargine in adult participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk
A joint initiative of the Public Health Agency of Canada, the Pan-Canadian Public Health Network, Statistics Canada and the Canadian Institute of Health Information
The combination produces greater weight loss than either medication alone
